Literature DB >> 1546950

The N-terminal domain of antithrombin-III is essential for heparin binding and complex-formation with, but not cleavage by, alpha-thrombin.

R C Austin1, W P Sheffield, R A Rachubinski, M A Blajchman.   

Abstract

Normal and mutant forms of human antithrombin-III (AT-III) were synthesized in a cell-free system in order to identify putative functional domains required for heparin binding and complex-formation with alpha-thrombin. Heparin-Sepharose chromatography resulted in the elution of approx. 70% of cell-free-derived normal AT-III-(1-432)-polypeptide as a peak between 0.2 M- and 0.7 M-NaCl. The cell-free-derived normal AT-III also reacted with alpha-thrombin. Approx. 15% of this AT-III formed covalent complexes with alpha-thrombin in 2 min. Unfractionated heparin accelerated the rate of formation of such complexes. Two truncated forms of AT-III (amino acid residues 219-432 and 251-432), containing only the putative thrombin-binding domain, were synthesized independently in this cell-free system. These truncated AT-III polypeptides did not bind heparin and were unable to form stable covalent complexes with alpha-thrombin. However, both of these AT-III polypeptides were cleaved by alpha-thrombin, presumably at the reactive centre Arg-393-Ser-394. The formation of the disulphide bond between Cys-247 and Cys-430 in AT-III-(219-432)-polypeptide had no effect on the results obtained. Mutations in full-length AT-III at Cys-430 had no effect on the ability of AT-III to bind heparin. There was, however, a slight decrease in the formation of stable inhibitory complexes with alpha-thrombin. A cell-free-derived AT-III mutant, devoid of amino acid residues 41-49, which comprise heparin-binding region 1 of AT-III, had slightly decreased heparin binding compared with cell-free-derived normal AT-III-(1-432)-polypeptide. This mutant AT-III polypeptide was unable, however, to form a stable complex with alpha-thrombin. We conclude therefore that the N-terminal domain of AT-III is essential for both heparin binding and complex-formation with alpha-thrombin, but not for the cleavage of AT-III at its reactive centre by alpha-thrombin.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1546950      PMCID: PMC1130785          DOI: 10.1042/bj2820345

Source DB:  PubMed          Journal:  Biochem J        ISSN: 0264-6021            Impact factor:   3.857


  33 in total

Review 1.  The molecular pathology of inherited human antithrombin III deficiency.

Authors:  H E Manson; R C Austin; F Fernandez-Rachubinski; R A Rachubinski; M A Blajchman
Journal:  Transfus Med Rev       Date:  1989-10

2.  Crystal structure of ovalbumin as a model for the reactive centre of serpins.

Authors:  P E Stein; A G Leslie; J T Finch; W G Turnell; P J McLaughlin; R W Carrell
Journal:  Nature       Date:  1990-09-06       Impact factor: 49.962

3.  The structural elements of hirudin which bind to the fibrinogen recognition site of thrombin are exclusively located within its acidic C-terminal tail.

Authors:  J Y Chang; P K Ngai; H Rink; S Dennis; J M Schlaeppi
Journal:  FEBS Lett       Date:  1990-02-26       Impact factor: 4.124

4.  A monoclonal antibody that triggers deacylation of an intermediate thrombin-antithrombin III complex.

Authors:  S Asakura; M Matsuda; N Yoshida; S Terukina; H Kihara
Journal:  J Biol Chem       Date:  1989-08-15       Impact factor: 5.157

Review 5.  Implications of the three-dimensional structure of alpha 1-antitrypsin for structure and function of serpins.

Authors:  R Huber; R W Carrell
Journal:  Biochemistry       Date:  1989-11-14       Impact factor: 3.162

6.  Re-formation of disulphide bonds in reduced antithrombin III.

Authors:  X J Sun; J Y Chang
Journal:  Biochem J       Date:  1990-08-01       Impact factor: 3.857

7.  Heparin binding domain of antithrombin III: characterization using a synthetic peptide directed polyclonal antibody.

Authors:  J W Smith; N Dey; D J Knauer
Journal:  Biochemistry       Date:  1990-09-25       Impact factor: 3.162

8.  Substrate properties of C1 inhibitor Ma (alanine 434----glutamic acid). Genetic and structural evidence suggesting that the P12-region contains critical determinants of serine protease inhibitor/substrate status.

Authors:  K Skriver; W R Wikoff; P A Patston; F Tausk; M Schapira; A P Kaplan; S C Bock
Journal:  J Biol Chem       Date:  1991-05-15       Impact factor: 5.157

9.  Predictions of the secondary structure of antithrombin III and the location of the heparin-binding site.

Authors:  G B Villanueva
Journal:  J Biol Chem       Date:  1984-02-25       Impact factor: 5.157

10.  Antithrombin activity of a peptide corresponding to residues 54-75 of heparin cofactor II.

Authors:  G L Hortin; D M Tollefsen; B M Benutto
Journal:  J Biol Chem       Date:  1989-08-25       Impact factor: 5.157

View more
  2 in total

1.  Cloning of the full-length cDNA of porcine antithrombin III and comparison with its human homolog.

Authors:  Younan Chen; Weidong Tan; Shengfang Qin; Jie Zhang; Hong Bu; Youping Li; Yanrong Lu; Jingqiu Cheng
Journal:  Comp Med       Date:  2009-08       Impact factor: 0.982

2.  In-vitro suppression of IL-6 and IL-8 release from human pulmonary epithelial cells by non-anticoagulant fraction of enoxaparin.

Authors:  Madhur D Shastri; Niall Stewart; James Horne; Gregory M Peterson; Nuri Gueven; Sukhwinder S Sohal; Rahul P Patel
Journal:  PLoS One       Date:  2015-05-11       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.